Navigation Links
Chakshu Research Announces Appointment of Dr. Randall Olson as Director
Date:2/11/2008

LOS GATOS, Calif., Feb. 11 /PRNewswire/ -- Chakshu Research, a specialty pharmaceutical company targeted at developing a non-surgical treatment for cataract and other degenerative ocular diseases, announced the addition of Dr. Randall J. Olson, M.D., to its Board of Directors in October of 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080211/AQM073ALOGO)

Dr. Olson is the CEO of the John A. Moran Eye Center and serves as the Chairman of the Department of Ophthalmology and Visual Sciences at the University of Utah. The department is recognized internationally for its research on the complications associated with intraocular lenses.

Dr. Olson was fascinated with Chakshu's early results and wanted to help bring the clinical science to a level of some clarity regarding the potential impact on cataract formation associated with aging. "With proven safety and continued good efficacy trends, Chakshu stands to be the first to offer a non-surgical cataract treatment for such an unmet medical need. Because of this and their trending toward potential treatment for other common eye diseases, I am committed to working with them in hopes of providing additional care for today's unserved patients."

He is the author of more than 300 professional publications and a worldwide lecturer. In addition to specializing in research dealing with intraocular lens complications, Dr. Olson also specializes in teleophthalmology and corneal transplantation techniques. He was selected as one of the 15 best cataract surgeons in the United States in a peer survey conducted by Ophthalmology Times. Cataract and Refractive Surgery Today named Dr. Olson as one of 50 international opinion leaders. He has appeared in the last three editions of Best Doctors in America.

After completing his undergraduate training and medical schooling at the University of Utah (BA '70, MD '73), he completed his residency at UCLA's Jules Stein Eye Institute in 1977. He went on to complete fellowships in cornea and external disease at the University of Florida in Gainesville and at the LSU Eye Center in New Orleans, where he joined the faculty in 1977 as Director of Corneal Services.

Dr. Olson joined the University of Utah faculty as an associate professor and division chief in 1979.

About Chakshu Research

Chakshu Research is a specialty pharmaceutical company committed to discovering treatments for degenerative ocular diseases. They have developed a topical drug, C-KAD Ophthalmic Solution (C-KAD OS), targeted to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases such as cataract, glaucoma, dry AMD, diabetic retinopathy and uveitis. The company is currently in clinical trials for cataract and glaucoma.

http://www.chakshu.com


'/>"/>
SOURCE Chakshu Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):